



PARABOLIC DRUGS LTD.

CIN No. : L24231CH1996PLC017755.

Ref: PDL: FEB: 2018

Dated: 13.02.2018

The National Stock Exchange of India Limited
"Exchange Plaza", Banda Kurla Complex
Bandra East, Mumbai
Maharashtra

Listing Compliance Cell
BSE Limited
PhirozeJeejeebhoy Towers
Dalal Street, Mumbai

**SUBJECT: SUBMISSION OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON
31st DECEMBER, 2017 !**

Sir/Madam


Pursuant to Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Unaudited Financial Results of the Company for the quarter ended on 31ST December, 2017 as approved by the Board of Directors in its meeting held on Monday, the 13th day of February, 2018, along with the Report of Auditor.

You are requested to display the same on the Notice Board of your Exchange for the information of members and general public.

For & On Behalf of ParabolicDrugs Limited

Sincerely

For Parabolic Drugs Ltd


Authorized Signatory

Authorized Signatory

V.K. JINDAL & ASSOCIATES
CHARTERED ACCOUNTANTS
gautamjindal1959@yahoo.in

PLOT NO. 5, SECTOR-1
INDUSTRIAL AREA,
PARWANOO.
PH. 01792-233229.
MOB. NO. 08699229555

Independent Auditor's Review Report on Standalone Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015

We have reviewed the accompanying statement of unaudited standalone financial results ("Statement") of M/s Parabolic Drugs Limited ("the Company") having Registered Office at SCO 99-100, Top Floor, Sector-17B, Chandigarh for the Quarter/Nine Months ended 31st December, 2017 being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the entity*, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above and **subject to Annexure-A**, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable Indian accounting standards (Ind AS) specified under section 133 of the Companies Act, 2013 and SEBI Circulars CIR/CFD/CMD/15/2015 dated 30 November 2015 and CIR/CFD/FAC/62/2016 dated 5 July 2016 , and other recognized accounting practices and policies has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Chandigarh;


Dated: 13th February,2018

FOR V K JINDAL & ASSOCIATES.,
CHARTERED ACCOUNTANTS

FRN No.005244N

(Vijay Jindal)

Partner



Membership No: 084128

V.K. JINDAL & ASSOCIATES
CHARTERED ACCOUNTANTS
gautamjindal1959@yahoo.in

PLOT NO. 5, SECTOR-1
INDUSTRIAL AREA,
PARWANOO.
PH. 01792-233229.
MOB. NO. 08699229555

Annexure A

Notes on the Un audited financial results of M/s Parabolic Drugs Limited

For the Quarter/Nine Months ended 31st December, 2017

1. Debit or Credit Balances on whatever account are subject to confirmation.
2. Depreciation has been provided for on pro-rata basis as per Companies Act, 2013.
3. Figures of the previous year/Quarter/Nine months have been rearranged/regrouped wherever considered necessary.

Chandigarh;


Dated: 13th February, 2018

FOR V K JINDAL & ASSOCIATES.,
CHARTERED ACCOUNTANTS

FRN No. 005244N

(Vijay Jindal)

Partner



Membership No: 084128



PARABOLIC DRUGS LTD.

CIN No. : L24231CH1996PLC017755.

Parabolic Drugs Limited
Registered Office: SCO. 99 - 100, Top Floor, Sector - 17B, Chandigarh
Statement of Un-audited Financial Results for the Quarter/ nine months ended 31st December 2017

Sr. No.	Particulars	(Rs. In Crore)					
		3 months ended			9 months ended		Previous year ended
		31.12.2017 Unaudited	30.09.2017 Unaudited	31.12.2016 Unaudited	31.12.2017 Unaudited	31.12.2016 Unaudited	31.03.2017 Audited
I	Revenue from Operations						
	(a) Net Sales (Net of duties)	16.28	23.96	24.26	55.57	49.24	69.12
	(b) Other Operating Income	0.11	0.00	1.61	0.81	2.40	4.60
	Total Revenue from Operations (Net of Excise Duty)	16.39	23.96	25.87	56.38	51.64	73.72
II	Other Income	(0.04)	0.34	2.20	4.08	3.99	4.25
III	Total Income (I + II)	16.35	24.30	28.07	60.46	55.63	77.97
IV	Expenses:						
	(a) Cost of materials consumed	12.53	21.53	22.35	48.08	44.49	64.08
	(b) Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods work-in-progress and Stock-in-Trade	2.19	(0.88)	(2.70)	1.28	22.47	27.86
	(d) Employees benefits expense	2.57	2.46	2.52	7.40	6.33	8.68
	(e) Finance Cost	1.90	1.80	32.50	6.26	92.72	9.91
	(f) Depreciation and amortization expense	8.65	8.65	13.38	25.95	40.15	53.49
	(g) Other expenses	3.60	4.52	4.69	12.52	13.14	19.19
	Total expenses (IV)	31.43	38.03	72.75	101.48	219.30	183.20
V	Profit / (Loss) before exceptional and extraordinary items and tax (III-IV)	(15.08)	(13.73)	(44.68)	(41.02)	(163.67)	(105.23)
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit / (Loss) before extraordinary items and tax (V - VI)	(15.08)	(13.73)	(44.68)	(41.02)	(163.67)	(105.23)
VIII	Tax expenses:						
	(a) Current tax	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Deferred tax	0.39	0.45	0.77	1.29	2.32	3.05
IX	Net Profit / (Loss) after tax from Continuing Operations (VII-VIII)	(15.47)	(14.23)	(45.45)	(42.31)	(165.99)	(108.28)
X	Other Comprehensive Income	0.00	0.00	0.05	0.00	0.16	0.21
XI	Total Comprehensive Income / (Expense) (Net of Tax)	(15.47)	(14.23)	(45.40)	(42.31)	(165.83)	(108.07)
XII	Paid-up Equity share capital (Face value of Rs.10/- each)						
	- Issued and Subscribed Capital	61.89	61.89	61.89	61.89	61.89	61.89
XIII	Earning Per Share (EPS) (Equity shares of Rs. 10/- each fully paid up)						
	a) Basic in Rs.	(2.50)	(2.30)	(7.33)	(6.84)	(26.79)	(17.46)
	b) Diluted in Rs.	(2.50)	(2.30)	(7.33)	(6.84)	(26.79)	(17.46)

Notes :

- The above quarterly results have been reviewed & recommended by the Audit Committee and taken on record by the Board of Directors in their meeting held on 13th February 2018 and the same have been reviewed by the Statutory Auditors.
- During the period under review, the company has incurred loss owing to the unfavorable market conditions interest burden and economic stress, the company has witnessed an erosion in the margins of key products.
- The promoters' shareholding (22619927 Equity shares) has been pledged pursuant to the terms of CDR package.
- The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.
- During the quarter ended 31st Dec,2017, most of Banks have not charged interest due to NPA Status of Loan Accounts. Hence no Provision for interest for the quarter ended 31st Dec, 2017 on these loans has been made on the belief that such interest would be waived at the time of final settlement.
- Finance Cost includes Price Difference of Raw material charged by the supplier

8. As per Ind AS 19, Revenue for the quarter / nine month ended December,2017 is reported net of duties.

9. The Profit / Loss reported in accordance with the Indian GAAP to total comprehensive Income in accordance with the Ind AS for the quarter ended December 31, 2016 is given below.

Particulars	Quarter ended December 31, 2016	Nine months ended December 31, 2016
Profit / Loss after tax reported under previous I-GAAP	(45.45)	(165.83)
Actuarial (Gain) / Loss on employee defined plans recognized in other Comprehensive Income	(0.05)	(0.21)
Net Profit / Loss after Tax As per Ind AS	(45.76)	(166.04)
Other Comprehensive Income as per Ind AS	0.03	0.21
Total Comprehensive Income as per Ind AS	(45.40)	(165.83)

Place : Chandigarh
 Date : 13th Feb 2018

For Parabolic Drugs Limited

Pranav Gupta
 Managing Director

Regd. & Corp. Office : S.C.O. 99 - 100, Top Floor, Sector 17 - B,
 Chandigarh - 160 017 (India) Tel. : +91-172-3914646, 3914647

Works - I : Village Sundhran, P.O. Mubarakpur, Dera Bassi,
 Distt. Mohali, Punjab, India Tel. : +91-1762 -308657
 website : www.parabolicdrugs.com